Temporary paralysis is the goal of Botulinum toxin and its alternatives, to stave off age-related wrinkles. However, the inventors on this patent take a more "muted" approach: by inhibiting the release of neurotransmitters signaling muscle contraction.
Peptide-based neurotransmitter inhibitors
U.S. Patent 9248089
Publication date: Feb. 2, 2016
Assignee: GRF (Wuhan) Biotechnology, Inc.
This patent is directed toward peptide-based compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof, which impart and anti-wrinkle effect by inhibiting neurotransmitter release and, in turn, muscle contraction. These compounds may be used for pathological neuronal exocytosis-mediated cosmetic and/or therapeutic purposes.
Furthermore, the invention is said to solve for the problem of peptides in zwitterion forms, which are not efficiently applicable topically, by modifying their structure to increase permeability into target cells.
